OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Randall on the Identification and Management of Non-Ossifying Fibromas

August 29th 2025

R. Lor Randall, MD, FACS, discusses the management of non-ossifying fibromas, and how this differs from that of malignant tumors.

Dr Desai on Research Informing Upfront CDK 4/6 Inhibitor Use in HR+/HER2– Breast Cancer

August 29th 2025

Neelam Desai, MD, discusses the current body of evidence for CDK 4/6 inhibitor use in metastatic HR-positive, HER2-negative breast cancer.

Dr Mouabbi on Areas for Further Investigation in HER2+ Breast Cancer

August 28th 2025

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma

August 28th 2025

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Dr Vose on the Development of Epcoritamab in Relapsed/Refractory DLBCL

August 28th 2025

Julie M. Vose, MD, MBA, details the rationale for evaluating epcoritamab for the treatment of patients with relapsed/refractory DLBCL with limited options.

Dr Tan on the Management of ADC-Related Toxicities in Breast Cancer

August 28th 2025

Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.

Dr Necchi on Molecular Data With Perioperative Sacituzumab Govitecan Plus Pembrolizumab in MIBC

August 28th 2025

Andrea Necchi, MD, discusses biomarker data with perioperative sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible MIBC.

Dr Qin on the Design of the HARMONY Trial of Niraparib-Based Therapy in mHSPC

August 28th 2025

Qian (Janie) Qin, MD, discusses the unique design of the phase 2 HARMONY trial of first-line niraparib plus abiraterone acetate and prednisone in mHSPC.

Dr Dimopoulos on BVd vs DVd in Relapsed/Refractory Multiple Myeloma With High-Risk Cytogenetic Features

August 27th 2025

Meletios A. Dimopoulos, MD, discusses the efficacy of BVd vs DVd in patients with relapsed or refractory multiple myeloma.

Dr Vento on the Clinical Significance of Somatic NGS in Guiding Treatment Decisions for Non–Clear Cell RCC

August 27th 2025

Joseph Vento, MD, discusses the importance of using somatic NGS to guide treatment decision-making for patients with non–clear cell RCC.

Dr Hanna on the Pharmacokinetic Profile of Micvotabart Pelidotin in HNSCC

August 27th 2025

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and manageable safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

Dr Morgans on the Rationale for Evaluating Darolutamide Plus ADT in High-Risk Biochemical Recurrence of Prostate Cancer

August 27th 2025

Alicia Morgans, MD, MPH, discusses the background of darolutamide plus ADT in patients with prostate cancer with high-risk biochemical recurrence.

Dr Malhotra on Persisting Knowledge Gaps Surrounding the Use of ADCs in Lung Cancer

August 27th 2025

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Dr Nathan on the Rationale for Evaluating Roginolisib in Advanced Ocular or Uveal Melanoma

August 27th 2025

Paul Nathan, MBBS, PhD, MRCP, details the rationale for evaluating roginolisib in patients with advanced or metastatic ocular or uveal melanoma.

Dr Simpkins on the Clinical Applicability of Cyclin E1 Protein Expression as a Biomarker for Response to Azenosertib in Ovarian Cancer

August 26th 2025

Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Dr Bedke on Advice for Using Enfortumab Vedotin/Pembrolizumab in Previously Untreated Advanced Urothelial Carcinoma

August 26th 2025

Jens Bedke, MD, discusses considerations for using enfortumab vedotin plus pembrolizumab in the frontline setting for advanced urothelial carcinoma.

Paulus on Research With a Real-World External Control Arm in HER2+ Breast Cancer

August 25th 2025

Jessica Paulus, ScD, discusses the development of a real-world control arm to inform the utility of findings from a trial in HER2-positive breast cancer.

Dr Farolfi on Real-World Outcomes With Bevacizumab Plus SOC in Cervical Cancer

August 25th 2025

Alberto Farolfi, MD, PhD, discusses real-world findings with bevacizumab plus platinum-based chemotherapy and pembrolizumab in advanced cervical cancer.

Dr Sarma on the Current Role of Sentinel Node Biopsies in Breast Cancer

August 25th 2025

Deba Sarma, MD, highlights the role of sentinel node biopsies ahead of surgery for the treatment of patients with breast cancer.

Dr Dorritie on the Management of Untreated and Relapsed/Refractory CLL

August 25th 2025

Kathleen A. Dorritie, MD, details the difference in care between the management of untreated CLL and relapsed/refractory CLL.